AU3236793A - Recombinant and chimeric antibodies to c-erbB-2 - Google Patents

Recombinant and chimeric antibodies to c-erbB-2

Info

Publication number
AU3236793A
AU3236793A AU32367/93A AU3236793A AU3236793A AU 3236793 A AU3236793 A AU 3236793A AU 32367/93 A AU32367/93 A AU 32367/93A AU 3236793 A AU3236793 A AU 3236793A AU 3236793 A AU3236793 A AU 3236793A
Authority
AU
Australia
Prior art keywords
erbb
recombinant
chimeric antibodies
chimeric
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU32367/93A
Inventor
John W Brandis
Hsiao-Lai C Liu
Michael P McBrogan
Deborah L Parkes
Laura K Shawver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Berlex Laboratories Inc
Original Assignee
Berlex Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US808462 priority Critical
Priority to US80846291A priority
Application filed by Berlex Laboratories Inc filed Critical Berlex Laboratories Inc
Publication of AU3236793A publication Critical patent/AU3236793A/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
AU32367/93A 1991-12-12 1992-12-04 Recombinant and chimeric antibodies to c-erbB-2 Abandoned AU3236793A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US808462 1985-12-13
US80846291A true 1991-12-12 1991-12-12

Publications (1)

Publication Number Publication Date
AU3236793A true AU3236793A (en) 1993-07-19

Family

ID=25198826

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32367/93A Abandoned AU3236793A (en) 1991-12-12 1992-12-04 Recombinant and chimeric antibodies to c-erbB-2

Country Status (2)

Country Link
AU (1) AU3236793A (en)
WO (1) WO1993012220A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0861893A3 (en) * 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
WO1994005332A2 (en) * 1992-09-01 1994-03-17 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
US6448077B1 (en) 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
CN100443118C (en) 1999-08-27 2008-12-17 杰南技术公司 Dosages for treatment with anti-ErbB2 antibodies
PT1282443E (en) 2000-05-19 2009-12-04 Genentech Inc Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
EP2377555A3 (en) 2004-11-18 2011-11-23 Imclone LLC Antibodies against vascular endothelial growth factor receptor-1
KR20130089280A (en) 2005-01-21 2013-08-09 제넨테크, 인크. Fixed dosing of her antibodies
MX2007009889A (en) 2005-02-23 2007-09-07 Genentech Inc Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor.
TWI352199B (en) 2007-03-02 2011-11-11 Genentech Inc Predicting response to a her inhibitor
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
ES2417148T3 (en) 2007-06-08 2013-08-06 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
AU2010226453B2 (en) 2009-03-20 2013-11-21 Genentech, Inc. Bispecific anti-HER antibodies
EP2435071A1 (en) 2009-05-29 2012-04-04 F.Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
MY160556A (en) 2010-02-18 2017-03-15 Genentech Inc Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
JP5766296B2 (en) 2010-12-23 2015-08-19 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components
EP2744824A1 (en) 2011-08-17 2014-06-25 F.Hoffmann-La Roche Ag Neuregulin antibodies and uses thereof
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
JP2015500638A (en) 2011-11-30 2015-01-08 ジェネンテック, インコーポレイテッド ERBB3 mutations in cancer
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
BR112015012644A2 (en) 2012-11-30 2017-12-19 Hoffmann La Roche method for determining a cancer patient's need, cancer treatment method, pharmaceutical composition, use of a nucleic acid or antibody and kit;
EP3454863A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies

Also Published As

Publication number Publication date
WO1993012220A1 (en) 1993-06-24

Similar Documents

Publication Publication Date Title
GB2257145B (en) Recombinant antibodies specific for TNFalpha
EP0648228B8 (en) Bnp antibody and immunoassay using it
AU646009B2 (en) Humanised antibodies
AU667502B2 (en) Chimeric immunogens
AU664975B2 (en) Chimeric neurotrophic factors
AU648398B2 (en) Mixed specificity fusion proteins
ZA9400447B (en) Fuel composition
EP0707596A4 (en) Conjugation-stabilized polypeptide compositions
ZA9302597B (en) Extended cement composition
GB9022648D0 (en) Polypeptide and its use
AU645187B2 (en) Freeze-dried preparation containing monoclonal antibody
AU7713291A (en) Modified acrylic capstock
AU1449892A (en) Modified factor vii
AU8754191A (en) Modified antibodies with controlled clearance time
AU7812391A (en) Glass composition
GB9225453D0 (en) Binding proteins
AU1645092A (en) Binder interface structure
AU6396294A (en) Polyester composition
AU4719393A (en) Expression of recombinant fusion proteins in attenuated bacteria
GB9219524D0 (en) Novel composition
AU7873694A (en) Alteration of immune response using pan dr-binding peptides
EP0861893A3 (en) High level expression of immunoglobulin polypeptides
SG48121A1 (en) Double-seal elsatomeric stopper
AU4621789A (en) Antibodies specific for elam-1 and the use thereof
GEP20074141B (en) Humanized heregulin antibody